Commerzbank reiterated their buy rating on shares of Qiagen (NASDAQ:QGEN) in a report published on Wednesday.

Several other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Qiagen from a buy rating to a hold rating in a research note on Monday, October 16th. Deutsche Bank restated a buy rating on shares of Qiagen in a research note on Wednesday, November 8th. TheStreet upgraded shares of Qiagen from a c+ rating to a b+ rating in a research note on Tuesday, November 7th. Cowen reiterated a hold rating and set a $34.00 price objective on shares of Qiagen in a research note on Thursday, December 21st. Finally, DZ Bank reiterated a neutral rating on shares of Qiagen in a research note on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $34.63.

Qiagen (QGEN) traded up $0.46 during mid-day trading on Wednesday, hitting $32.65. 723,291 shares of the company traded hands, compared to its average volume of 998,460. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen has a fifty-two week low of $27.51 and a fifty-two week high of $36.34. The firm has a market capitalization of $7,540.00, a P/E ratio of 83.72, a PEG ratio of 1.80 and a beta of 1.10.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The business had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. During the same period in the prior year, the company posted $0.29 earnings per share. Qiagen’s revenue was up 7.5% compared to the same quarter last year. equities research analysts anticipate that Qiagen will post 1.25 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in QGEN. Atlanta Capital Management Co. L L C grew its stake in Qiagen by 210.1% during the third quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock worth $41,400,000 after buying an additional 890,454 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Qiagen during the second quarter worth about $26,408,000. WINTON GROUP Ltd acquired a new stake in shares of Qiagen in the 2nd quarter valued at approximately $15,088,000. Vanguard Group Inc. boosted its stake in shares of Qiagen by 7.0% in the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after purchasing an additional 394,201 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Qiagen by 127.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 652,285 shares of the company’s stock valued at $20,521,000 after purchasing an additional 365,732 shares in the last quarter. Hedge funds and other institutional investors own 62.09% of the company’s stock.

WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/qiagen-qgen-rating-reiterated-by-commerzbank/1807090.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.